Last updated: February 23, 2026
What is NDC 82009-0050?
NDC 82009-0050 refers to a specific drug product listed in the National Drug Code (NDC) database. It is marketed by BioRx, a biopharmaceutical company. The product is an injectable biologic therapy used primarily in oncology indications.
Market Size and Demand Drivers
Global Biologics Market Context
The biologics market was valued at approximately $330 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.4% from 2023 to 2030, reaching around $617 billion [1].
Specific Indication and Patient Population
The drug targets refractory non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The prevalence of these conditions influences demand:
- NHL prevalence: 77,000 cases annually in the U.S. [2]
- MM prevalence: 34,000 cases in the U.S. [3]
The drug's market penetration depends on factors such as competition, clinical efficacy, and regulatory approval timelines.
Market Penetration and Competition
Main competitors include:
- Rituximab
- Daratumumab
- Elotuzumab
Market share among biologics for these indications is approximately 40% for rituximab, with the remaining 60% split among newer agents [4].
Geographic Market Breakdown
The U.S. accounts for about 45% of biologics sales globally. Europe makes up 30%, Asia-Pacific 15%, and the rest of the world 10% [1].
Regulatory and Reimbursement Dynamics
- FDA approval was granted on January 15, 2022, with full commercialization beginning Q2 2022.
- Medicare and private insurers cover the drug based on compendia listing, with negotiated pricing agreements.
- The average reimbursement rate for similar biologics ranges from $10,000 to $25,000 per vial, depending on dosing and indication [5].
Price Analysis and Projections
Current Pricing
The average wholesale price (AWP) for NDC 82009-0050 is approximately $15,000 per single-use vial as of Q1 2023.
Market Penetration and Revenue Assumptions
Assuming:
- Year 1: 10% market penetration among eligible patients
- Year 2: 20%
- Year 3: 30%
- Population eligible: 7,000 patients annually in the U.S.
Projected sales:
| Year |
Patients Treated |
Total Vials (per patient, average 2) |
Revenue ($ millions) |
| 2023 |
700 |
1,400 |
21 |
| 2024 |
1,400 |
2,800 |
42 |
| 2025 |
2,100 |
4,200 |
63 |
International expansion could increase revenue by 50% after 2025, factoring in clinical adoption rates and payer acceptance.
Price Trajectory
- Short-term (2023-2025): Stable at ~$15,000 per vial.
- Medium-term (2026-2030): Moderate price erosion of 3-5% annually owing to biosimilar competition and increased market saturation.
- Long-term (beyond 2030): Potential stabilization at around $10,000-$12,000 per vial depending on biosimilar entry and regulatory changes.
Risks and Opportunities
Risks
- Biosimilar entrants expected from 2027, potentially reducing pricing power.
- Regulatory delays or new safety data impacting reimbursement.
- Competition from heavily financed pipeline drugs.
Opportunities
- Expansion into emerging markets with limited biologic access.
- New indications expanding patient population.
- Development of biosimilars that could lower market barriers.
Key Price Drivers
- Dosing protocols: Average dose per patient influences total revenue.
- Reimbursement negotiations: Payer willingness to pay impacts net sales.
- Exclusive licensing: Patent protections until 2030 protect pricing.
Key Takeaways
- The market for NDC 82009-0050 is driven by the prevalence of NHL and MM, with an increasing global biologics market.
- Current prices remain stable at around $15,000 per vial but are expected to decline modestly after biosimilar entry.
- Revenue projections for the next three years estimate $21 million to $63 million in the U.S., with international sales potentially adding significantly.
- Long-term outlook depends on biosimilar competition, regulatory developments, and market expansion.
FAQs
1. What factors influence the drug’s market share?
Clinical efficacy, safety profile, approval of new indications, reimbursement policies, and competition shape market share.
2. How are biosimilars impacting pricing?
Biosimilars are expected to cause price erosion starting around 2027, reducing revenue per vial by up to 30-50% over a decade.
3. What is the significance of geographic expansion for revenue?
Emerging markets with limited biologic access can significantly boost sales, especially once regulatory pathways are established.
4. How does regulatory approval influence pricing?
Approval accelerates market entry, allowing the manufacturer to set prices; delays may reduce anticipated revenue.
5. What are the key risks for investment in this biologic?
Market entry of biosimilars, regulatory delays, or off-label use restrictions pose primary risks.
References
[1] Grand View Research. (2022). Biologics Market Size, Share & Trends Analysis.
[2] American Cancer Society. (2022). Non-Hodgkin Lymphoma Facts & Figures.
[3] National Cancer Institute. (2021). Multiple Myeloma Overview.
[4] IQVIA. (2022). Biologics Market Share Data.
[5] Medicare.gov. (2023). Reimbursement Rates for Biologics.
Note: Data is based on publicly available sources and market assumptions. Actual performance may vary.
